Bcr-Abl

The Bcr/Abl fusion protein is localized to the cytoplasm and actin cytoskeleton of hematopoietic cells, and has increased and dysregulated tyrosine kinase activity.

Cat. No.	Product name	CAS No.	Purity
T34656	SKLB 1028	1350544-93-2	99.85%
T34656	SKLB 1028 (Ruserontinib) is a new type of oral multikinase inhibitor of EGFR, FLT3, and Abl. SKLB 1028 shows excellent activity in FLT3-driven AML models and con...
T0152	Bosutinib	380843-75-4	99.84%
T0152	Bosutinib (SKI-606) is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl (IC50: 1 nM) and Src (IC50: 1.2 nM) kinases.
T2640	Rebastinib	1020172-07-9	99.84%
T2640	DCC-2036 (Rebastinib (DCC-2036)) is a conformational control Bcr-Abl inhibitor for Abl1(WT, IC50: 0.8 nM) and Abl1(T315I, IC50: 4 nM), also inhibits LYN, SRC, HC...
T1524	Nilotinib	641571-10-0	99.83%
T1524	Nilotinib (AMN107) is a second-generation Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.
T6196	PP1	172889-26-8	99.82%
T6196	PP1 (AGL 1872), a specific and effective Src inhibitor, is with IC50 for Lck/Fyn is 5 nM/ 6 nM, respectively.
T7861	Flumatinib mesylate	895519-91-2	99.82%
T7861	Flumatinib mesylate (HHGV678 mesylate) is a selective inhibitor of c-Abl, PDGFRβ and c-Kit, effectively overcomes drug resistance of certain KIT mutants.
T2429	Olverembatinib dimesylate	1421783-64-3	99.81%
T2429	Olverembatinib dimesylate (GZD824 Dimesylate) is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I).
T1803	GNF-5	778277-15-9	99.78%
T1803	GNF-5 is a specific non-ATP competitive inhibitor of Bcr-Abl (IC50: 0.22±0.1 uM, Wild-type Abl). It is an analog of GNF-2 with improved pharmacokinetic propertie...
T2372	Ponatinib	943319-70-8	99.74%
T2372	Ponatinib (AP24534) is an orally available, multitargeted kinase inhibitor (IC50s: 0.37/1.1/1.5/2.2/5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively)...
T1621	Imatinib Mesylate	220127-57-1	99.73%
T1621	Imatinib Mesylate (STI-571) is a tyrosine kinase receptor inhibitor with antineoplastic activity (IC50s: 0.6 μM, 0.1 μM and 0.1 μM for v-Abl, c-Kit and PDGFR, re...
T15164	DPH	484049-04-9	99.72%
T15164	DPH is a potent cell permeable activator of c-Abl. It shows potent enzymatic and cellular activity in stimulating c-Abl activation.
T2147	Nilotinib monohydrochloride monohydrate	923288-90-8	99.7%
T2147	Nilotinib monohydrochloride monohydrate (Nilotinib (monohydrochloride monohydrate)) is significantly potent BCR-ABL against, is a second generation tyrosine kina...
T2328	Radotinib	926037-48-1	99.7%
T2328	Radotinib (IY-5511), and sometimes referred to by its investigational name IY5511, is a drug for the treatment of different types of Y, most notably Philadelphia...
T6311	Bafetinib	859212-16-1	99.68%
T6311	Bafetinib (INNO-406) (INNO-406) is an effective and specific dual Bcr-Abl/Lyn inhibitor (IC50: 5.8/19 nM), and no inhibition of the phosphorylation of the T315I ...
TN2211	Silybin B	142797-34-0	99.66%
TN2211	Silybin B (Silibinin B) is an effective inhibitor of raloxifene 4 '- and 6-glucosalylation, an effective anti-fibrinogenic and anti-oligomeric component of Silym...
T2293	SGX-523	1022150-57-7	99.6%
T2293	SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf.
T5177	Asciminib	1492952-76-7	99.45%
T5177	Asciminib (ABL001) (ABL001) is a potent and selective Bcr-Abl inhibitor (Kd: 0.5–0.8nM).
T2920	Berbamine dihydrochloride	6078-17-7	99.38%
T2920	Berbamine dihydrochloride (Berbamine), a natural compound derived from the Berberis amurensis plant, has been shown to exhibit antitumor activity in several Ys.
T6128	PHA-665752	477575-56-7	99.35%
T6128	PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.
T2802	Nocodazole	31430-18-9	99.34%
T2802	Nocodazole (Oncodazole) is a reversible inhibitor of microtubule polymerization and an inhibitor of Bcr-Abl. Nocodazole has antitumor activity, blocks the cell c...